OrbiMed’s Milestone Pharmaceuticals MIST Stock Holding History

OrbiMed’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,221,828	Closed	-$6.44M	–	121
2025 Q3	$6.44M	Buy	+3,221,828	New	+$5.67M	0.15%	82
2025 Q1	–	Sell	-2,000,000	Closed	-$4.72M	–	119
2024 Q4	$4.72M	Hold	2,000,000	–	–	0.1%	88
2024 Q3	$3.04M	Hold	2,000,000	–	–	0.06%	105
2024 Q2	$2.64M	Hold	2,000,000	–	–	0.05%	99
2024 Q1	$3.58M	Buy	+2,000,000	New	+$3.25M	0.07%	101
2022 Q3	–	Sell	-1,817,521	Closed	-$11.2K	–	140
2022 Q2	$11.2K	Sell	1,817,521 -766,300	-30%	-$4.71M	0.2%	87
2022 Q1	$16.6M	Hold	2,583,821	–	–	0.27%	75
2021 Q4	$16.9M	Hold	2,583,821	–	–	0.22%	94
2021 Q3	$14.8M	Hold	2,583,821	–	–	0.16%	110
2021 Q2	$14.2M	Hold	2,583,821	–	–	0.14%	111
2021 Q1	$15M	Buy	2,583,821 +90,712	+4%	+$664K	0.14%	109
2020 Q4	$16.7M	Buy	2,493,109 +2,107,318	+546%	+$14.1M	0.15%	108
2020 Q3	$2.82M	Buy	+385,791	New	+$2.77M	0.04%	134
2020 Q1	–	Sell	-364,206	Closed	-$5.83M	–	155
2019 Q4	$5.83M	Buy	+364,206	New	+$6.44M	0.08%	99

Other funds holding MIST

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

OrbiMed's MIST Position: Q4 2025 in Review

OrbiMed sold out of Milestone Pharmaceuticals (MIST) in Q4 2025, closing a stake of 3,221,828 shares — an estimated $6.44M sold.

OrbiMed first reported a position in MIST in Q4 2019 and held it in 14 quarters. The position peaked at $16.9M in Q4 2021. 79 funds tracked by Wall St. Rank hold MIST as of Q4 2025.

OrbiMed reported no remaining Milestone Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
OrbiMed sold 3,221,828 Milestone Pharmaceuticals shares in Q4 2025, an estimated $6.44M.
OrbiMed first reported a position in Milestone Pharmaceuticals in Q4 2019 and held it in 14 quarters.
OrbiMed's Milestone Pharmaceuticals position peaked at $16.9M in Q4 2021.
79 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2025.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.